<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951791</url>
  </required_header>
  <id_info>
    <org_study_id>lipid in cardiac surgery</org_study_id>
    <nct_id>NCT04951791</nct_id>
  </id_info>
  <brief_title>Lipid Emulsion in Cardiac Valve Replacement Surgery</brief_title>
  <official_title>Effects of Lipid Emulsion on Myocardial Protection and Inflammatory Response in Cardiac Valve Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocardial protection has become an essential adjunctive measure in cardiac surgery to bail&#xD;
      the myocardium out of ischemia/reperfusion-induced damage during the operation.&#xD;
&#xD;
      Experimental studies have shown that lipid emulsion infusion just before reperfusion (i.e.,&#xD;
      intralipid postconditioning (ILPC)) could reduce myocardial infarct sizes, improve cardiac&#xD;
      function, and reduce myocardial I/R injuries, despite the interesting experimental findings,&#xD;
      the potential clinical usage of lipid emulsion in preventing myocardial I/R injury needs to&#xD;
      be further investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study of myocardial protection has improved aiming to prevent intraoperative myocardial&#xD;
      injury, which can lead to ventricular dysfunction, arrhythmias, low cardiac output and other&#xD;
      complications, often irreversible ones.&#xD;
&#xD;
      Nowadays there are numerous methods of myocardial protection during cardiac surgery, But&#xD;
      still there is no best myocardial protection technique.&#xD;
&#xD;
      Despite improved myocardial protection strategies, cardioplegic arrest and ischemia still&#xD;
      result in ischemic reperfusion injury during cardiac surgery.&#xD;
&#xD;
      Many drugs have proved a pharmacological postconditioning effect on the heart at the onset of&#xD;
      reflow and had been shown to limit infarction size and decrease the ischemic/reperfusion&#xD;
      injury ,Postconditioning (POC) has been reported to promote left ventricular functional&#xD;
      recovery after global ischemia with cardioplegic arrest on cardiopulmonary bypass in a large&#xD;
      animal model Smoflipid is a sterile safe lipid emulsion comprised of soybean oil (30%),&#xD;
      medium chain triglycerides (30%) olive oil (25%) &amp; fish oil (15%) that has been associated&#xD;
      with decreased oxidative injury, improved liver function and increased antioxidant activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myocardium protection</measure>
    <time_frame>72 hours</time_frame>
    <description>assessment of lipid emulsion effect on post cardiopulmonary bypass ischemic reperfusion injury through measuring ( cardiac troponin (CTnI) in ng/ml )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory response</measure>
    <time_frame>72 hours</time_frame>
    <description>assessment of the inflammatory response to lipid emulsion infusion through measuring ( Interleukein-6 (IL-6) in ng/l ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>myocardium protection</measure>
    <time_frame>72 hours</time_frame>
    <description>assessment of lipid emulsion effect on post cardiopulmonary bypass ischemic reperfusion injury through (cardiac specific creatine kinase (CK-MB) in units/l )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory response</measure>
    <time_frame>72 hours</time_frame>
    <description>assessment of the inflammatory response to lipid emulsion infusion through measuring ( C Reactive protein (CRP) in mg/l )</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Ischemic Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive intravenous infusion of SMOFlipid 20%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will receive intravenous infusion of normal saline 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMOFlipid</intervention_name>
    <description>will receive intravenous infusion of 2ml\kg of smoflipid 20%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>smoflipid 20% lipid emulsion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline 0.9%</intervention_name>
    <description>will receive intravenous infusion of 2ml\kg of normal saline 0.9%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed.</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients undergoing rheumatic valve replacement surgery&#xD;
&#xD;
          -  elective surgery&#xD;
&#xD;
          -  age between 18 and 80 years old&#xD;
&#xD;
          -  left ventricular ejection fraction &gt; 0.4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency and Re do surgery,&#xD;
&#xD;
          -  Positive base line CTnI or CK-MB,&#xD;
&#xD;
          -  Preoperative treatment with intralipid in the last 1 month.&#xD;
&#xD;
          -  History of allergy to (peanut, eggs, and soya bean)&#xD;
&#xD;
          -  Implanted pacemaker,&#xD;
&#xD;
          -  previous myocardial infarction,&#xD;
&#xD;
          -  Diabetic or other metabolic disorders,&#xD;
&#xD;
          -  Significant Renal impairment (Cr &gt; 1.5) or on hemodialysis&#xD;
&#xD;
          -  Significant hepatic dysfunction (INR&gt;2)&#xD;
&#xD;
          -  Drugs interfere as (cyclosporine)&#xD;
&#xD;
          -  Infection (WBC &gt;12)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>sara abdallah</last_name>
    <phone>01009556520</phone>
    <email>sara92abdallah@gmail.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>sara abdallah</investigator_full_name>
    <investigator_title>Assisstant lecturer of anesthesia and intensive care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SMOFlipid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

